Pharmacyclics Inc (PCYC)

PCYC (NASDAQ:Drugs)
$116.91
neg -3.53
-2.93%
Today's Range: 112.60 - 122.25 | PCYC Avg Daily Volume: 1,268,600
Last Update: 08/01/14 - 4:00 PM EDT
Volume: 2,263,145
YTD Performance: 13.86%
Open: $119.57
Previous Close: $120.44
52 Week Range: $82.51 - $154.89
Oustanding Shares: 75,032,044
Market Cap: 9,260,454,870
6-Month Chart
TheStreet Ratings Grade for PCYC
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 10 9 8 10
Moderate Buy 0 0 0 1
Hold 5 6 7 5
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.67 1.80 1.93 1.69
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 67.44
Price Earnings Comparisons:
PCYC Sector Avg. S&P 500
67.44 69.60 28.90
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
27.34% 10.87% 862.75%
GROWTH 12 Mo 3 Yr CAGR
Revenue 61.90 26.95 2.00
Net Income -43.00 -5.46 0.00
EPS -45.00 -3.97 0.00
Earnings for PCYC:
EBITDA 0.10B
Revenue 0.26B
Average Earnings Estimates
Qtr (09/14) Qtr (12/14) FY (12/14) FY (12/15)
Average Estimate $-0.08 $0.24 $0.38 $0.31
Number of Analysts 7 7 6 9
High Estimate $0.47 $1.02 $1.00 $3.11
Low Estimate $-0.32 $-0.49 $-0.56 $-2.19
Prior Year $0.55 $0.82 $0.87 $0.38
Growth Rate (Year over Year) -114.29% -70.91% -55.94% -19.42%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
By

Jim Cramer

 | Jul 29, 2014 | 4:21 PM EDT

Something worrisome has me fretting more than I have in a while.

bullishPharmacyclics upgraded at Leerink

Jul 29, 2014 | 7:52 AM EDT

PCYC was upgraded from Market Perform to Outperform, Leerink Swann said. $142 price target. Expect that Zydelig and Imbruvica can drive near-term growth. 

bearishPharmacyclics downgraded at RBC

May 27, 2014 | 7:09 AM EDT

PCYC was downgraded from Outperform to Sector Perform, RBC Capital said. $95 price target. Company is facing potential growth headwinds. 

 

By

Gary Dvorchak

 | Jan 13, 2014 | 7:15 AM EST

For these names, targets have climbed ahead of earnings releases.

By

Jim Cramer

 | Jan 7, 2014 | 1:35 PM EST

These growth stocks are no longer an anchor to this market.

bearishPharmacyclics cut from Best Ideas List at Wedbush

Nov 14, 2013 | 8:05 AM EST

PCYC was removed from the Best Ideas list, Wedbush said. Patient assistance programs for Imbruvica will be restricted.

By

Jim Cramer

 | Nov 13, 2013 | 3:49 PM EST

Skittish buyers are only nibbling and leaving plenty of good cheap stocks for you.

bullishPharmacyclics upgraded at Goldman

Oct 11, 2013 | 7:37 AM EDT

PCYC was upgraded from Neutral to Buy, Goldman Sachs said. $170 price target. ibruttinib could generate $7.5 billion of peak annual sales. 

By

Gary Dvorchak

 | Oct 7, 2013 | 10:30 AM EDT

This trend is a good indication that business is going well.

bullishPharmacyclics rated new Overweight at JP Morgan

Sep 26, 2013 | 8:12 AM EDT

PCYC was initiated with an Overweight rating, JP Morgan said.J&J partnership should drive growth. 

Is this the biotech revolution or the biotech bust? View Small Cap Biotechs Like Never Bef...
Last year saw the MC NYSE oscillator hit -300 on about five occasions, and each time a mas...
If you are in the NYC area, Bob Lang and I will be in town this Monday and Tuesday night. ...
There are no signals in IWM....Still watching zone 2 in WYNN for a potential entry. The up...

REAL MONEY PRO'S BEST IDEAS

Columnist Tweets

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.